Pfizer Pays $55M For Off-Label Promotion Of Wyeth's Protonix

Law360, New York (December 12, 2012, 1:46 PM EST) -- Pfizer Inc. will pay $55 million to settle allegations that Wyeth LLC, which it bought three years ago, illegally promoted heartburn drug Protonix for off-label uses, the U.S. Department of Justice said Wednesday, the latest financial fallout from the merger.

Wyeth’s alleged misconduct in 2000 and 2001 included transforming continuing medical education programs at universities and nonprofit centers into promotional vehicles for the company, the DOJ said. While pharmaceutical companies can financially support such programs, Wyeth purportedly crossed the line by allowing a so-called brand team...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.